Aligos Therapeutics, Inc.

DB:5WK0 Stock Report

Market Cap: €62.4m

Aligos Therapeutics Past Earnings Performance

Past criteria checks 0/6

Aligos Therapeutics has been growing earnings at an average annual rate of 0.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 48.3% per year.

Key information

0.2%

Earnings growth rate

72.7%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate48.3%
Return on equity-153.6%
Net Margin-1,283.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Aligos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:5WK0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246-77233
30 Jun 248-76250
31 Mar 2414-100280
31 Dec 2316-88300
30 Sep 2316-82310
30 Jun 2317-82300
31 Mar 2314-83280
31 Dec 2214-96260
30 Sep 2211-112290
30 Jun 228-126300
31 Mar 226-136290
31 Dec 214-128290
30 Sep 214-125250
30 Jun 212-125230
31 Mar 211-116200
31 Dec 200-109180
30 Sep 200-921515
30 Jun 200-731427
31 Mar 200-621235
31 Dec 190-521044

Quality Earnings: 5WK0 is currently unprofitable.

Growing Profit Margin: 5WK0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 5WK0 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.

Accelerating Growth: Unable to compare 5WK0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5WK0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).


Return on Equity

High ROE: 5WK0 has a negative Return on Equity (-153.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies